Lithium: Why This Mood Stabiliser Might Be the Most Underrated Neuroprotective Mineral
When most people hear “lithium,” they think of the prescription mood stabiliser used for bipolar disorder — a medication that can be highly effective but also carries significant side effects and requires careful monitoring of blood levels. But there’s a different form of lithium that deserves serious attention in the longevity and cognitive optimisation space: lithium orotate. This is a form of lithium bound to orotic acid, which allows much lower doses to achieve meaningful concentrations in the brain — doses far below those used in psychiatric practice. At these lower doses, lithium appears to act as a neuroprotective agent through mechanisms that are genuinely exciting: promoting nerve growth factor, reducing glutamate toxicity, decreasing inflammation, and even showing anti-aging effects in the brain. The picture emerging from the research is that lithium — in the right form and dose — may be one of the most powerful agents for long-term brain health.
The neuroprotective mechanism of lithium is multifaceted and supported by an impressive body of research. It increases levels of brain-derived neurotrophic factor (BDNF) — the growth factor that supports neuron survival and the growth of new neural connections. It inhibits the activity of glycogen synthase kinase-3 (GSK-3), an enzyme that, when overactive, promotes neurodegeneration and tau protein aggregation (the pathological hallmark of Alzheimer’s disease). It reduces glutamate-induced excitotoxicity (the process by which overactive neural signalling damages neurons). And it activates the pro-survival autophagy pathways that help clear damaged proteins from brain cells. This combination of effects makes lithium a genuinely multi-target neuroprotective agent.
Lithium, Tau, and Alzheimer’s Research
The link between lithium and Alzheimer’s pathology is one of the most compelling areas of current research. GSK-3 is a key enzyme in the production of tau tangles, one of the two hallmark protein aggregations found in Alzheimer’s brains (along with amyloid beta plaques). Lithium inhibits GSK-3, potentially reducing tau pathology. Several observational studies have found that people with higher trace lithium intake (from drinking water) have lower rates of dementia. A landmark 2018 study published in Journal of Alzheimer’s Disease found that microdose lithium (1.5mg daily) reduced cognitive decline in people with mild cognitive impairment — a potential precursor to Alzheimer’s. This is early-stage but highly suggestive research.
The gut microbiome connection adds another dimension. Research over the past decade has established that lithium affects the gut microbiome in ways that may be relevant to both its neuropsychiatric effects and its metabolic actions. Different microbiome compositions influence how different individuals respond to lithium — a finding that may eventually allow more personalised lithium supplementation protocols. This is part of a broader shift in understanding how the gut-brain axis mediates the effects of neuropsychiatric medications.
Lithium Orotate vs Lithium Carbonate
Prescription lithium (lithium carbonate or lithium citrate at doses of 300–1,200mg daily) achieves blood levels of 0.6–1.2 mmol/L — doses that are close to the toxic threshold and require regular blood monitoring. Lithium orotate uses a different delivery system: the orotate salt is more readily taken up by cells, including brain cells, meaning that much lower doses (typically 5–20mg of elemental lithium) can achieve meaningful concentrations in neural tissue while keeping blood levels very low. This makes lithium orotate potentially useful for long-term neuroprotective applications without the need for blood monitoring. However, it’s worth noting that the evidence base for lithium orotate specifically is less extensive than for prescription lithium.
Key Takeaways
Lithium orotate at microdoses (5–20mg elemental lithium) appears to have neuroprotective effects through multiple mechanisms including BDNF increase, GSK-3 inhibition, and glutamate reduction. Research on lithium and Alzheimer’s prevention (particularly from water lithium studies and recent microdose trials) is compelling. Lithium orotate may be a practical form for cognitive protection without the monitoring requirements of prescription lithium. More research is needed, but this is one of the more interesting brain health interventions available.
Iron Role in Brain Energy Metabolism
Iron is essential for brain function far beyond its role in haemoglobin and oxygen transport. The brain consumes approximately 20% of the body oxygen despite accounting for only 2% of body weight, and iron is critical in this energy metabolism — particularly in the electron transport chain within mitochondria, where iron-sulfur clusters are essential components of Complexes I, II, and III. Iron is also a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, and for ribonucleotide reductase, the enzyme required for DNA synthesis. These roles mean that iron deficiency — even without frank anaemia — can impair dopaminergic signalling, reduce neural energy production, and compromise myelin formation, with measurable effects on attention, memory, and executive function.
Why Iron Deficiency Is So Common
Iron deficiency is the most common nutritional deficiency worldwide, affecting an estimated 2 billion people. In menstruating women, iron deficiency is particularly prevalent due to monthly menstrual blood loss — even a “normal” menstrual iron loss of 30-40ml per cycle can gradually deplete iron stores over months to years. In men and post-menopausal women, iron deficiency should always be investigated as it can signal occult gastrointestinal blood loss. The symptoms of iron deficiency extend well beyond fatigue and pallor: restless legs syndrome (strongly associated with brain iron deficiency), impaired thermoregulation, reduced exercise tolerance, and cognitive impairment in both children and adults.
Iron Status: Not Just Haemoglobin
The standard diagnostic marker for iron deficiency is haemoglobin — but this misses the majority of iron-deficient people, because haemoglobin only falls after iron stores (ferritin) are already significantly depleted. Ferritin is the storage form of iron, and a level below 30 ng/mL indicates depleted stores, while anything below 15 ng/mL indicates frank deficiency. Optimal ferritin for cognitive function appears to be in the range of 50-100 ng/mL. Iron supplementation should always be guided by ferritin testing, not haemoglobin alone, and excessive iron (from over-supplementation or haemochromatosis) carries its own serious risks including liver cirrhosis and increased infection risk through iron-dependent pathogen growth.
Leave a Reply